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Abstract
Background: Immunosuppressants such as mycophenolate mofetil (MMF) have the capacity to inhibit microglial
and astrocytic activation and to reduce the extent of cell death after neuronal injury. This study was designed to
determine the effective neuroprotective time frame in which MMF elicits its beneficial effects, by analyzing glial cell
proliferation, migration, and apoptosis.
Methods: Using organotypic hippocampal slice cultures (OHSCs), temporal dynamics of proliferation and apoptosis
after N-methyl-D-aspartate (NMDA)-mediated excitotoxicity were analyzed by quantitative morphometry of Ki-67 or
cleaved caspase-3 immunoreactive glial cells. Treatment on NMDA-lesioned OHSCs with mycophenolate mofetil
(MMF)100 μg/mL was started at different time points after injury or performed within specific time frames, and the
numbers of propidium iodide (PI)+ degenerating neurons and isolectin (I)B4
+ microglial cells were determined.
Pre-treatment with guanosine 100 μmol/l was performed to counteract MMF-induced effects. The effects of MMF
on reactive astrocytic scar formation were investigated in the scratch-wound model of astrocyte monolayers.
Results: Excitotoxic lesion induction led to significant increases in glial proliferation rates between 12 and 36 hours
after injury and to increased levels of apoptotic cells between 24 and 72 hours after injury. MMF treatment
significantly reduced glial proliferation rates without affecting apoptosis. Continuous MMF treatment potently
reduced the extent of neuronal cell demise when started within the first 12 hours after injury. A crucial time-frame
of significant neuroprotection was identified between 12 and 36 hours after injury. Pre-treatment with the
neuroprotective nucleoside guanosine reversed MMF-induced antiproliferative effects on glial cells. In the
scratch-wound model, gap closure was reached within 48 hours in controls, and was potently inhibited by MMF.
Conclusions: Our data indicate that immunosuppression by MMF significantly attenuates the extent of neuronal
cell death when administered within a crucial time frame after injury. Moreover, long-lasting immunosuppression,
as required after solid-organ transplantation, does not seem to be necessary. Targeting inosine 5-monophosphate
dehydrogenase, the rate-limiting enzyme of purine synthesis, is an effective strategy to modulate the temporal
dynamics of proliferation and migration of microglia and astrocytes, and thus to reduce the extent of secondary
neuronal damage and scar formation.
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Background
Acute pathologies of the central nervous system (CNS)
such as traumatic brain and spinal cord injury, excito-
toxicity, or cerebral ischemia cause immediate and irre-
versible damage to neurons, often associated with severe
neurological impairment. All acute lesions trigger patho-
physiological cascades that additionally involve delayed
loss of primarily unaffected neuronal cell populations,
the process known as secondary damage [1-4]. Within
the scope of this phenomenon, highly complex and dy-
namic neuron–glia interactions lead to the activation,
proliferation, and recruitment of astrocytes, microglial
cells, and blood-borne immune cells. To a certain extent,
inflammatory cascades carried by direct cell–cell interac-
tions via contact-dependent communication (such as
Ephrin receptors or repulsive guidance molecules) deter-
mine the mode and dimension of glial activation, glutamate
sensitivity or axonal regrowth [5-8]. Furthermore, the re-
lease of a variety of soluble factors from activated glial cells
modulates neuronal injury and recovery, as shown for pro-
and anti-inflammatory cytokines, nitric oxide, chemokines,
growth factors, prostaglandins, and reactive oxygen species
[9-14]. Consequently, neuroinflammatory responses in the
aftermath of acute neuropathologies may have detrimental
effects, suggesting that an inhibition of glial activation by
means of immunosuppression may be beneficial for neur-
onal survival and recovery [15-17].
Immunosuppressive drugs have been studied with re-
gard to their capacity to arrest secondary injury cascades
in a variety of models of acute CNS injury or ischemia.
However, the widespread use of steroids such as methyl-
prednisolone as acute pharmacological intervention after
spinal-cord injuries has recently been questioned be-
cause of reports of only marginal effects on neurological
outcome in clinical trials in opposition to the earlier
promising experimental evidence [18-20]. Other im-
munosuppressant agents such as the immunophilin
ligands ciclosporin A and FK506 (tacrolimus) likewise
produced improvement neuronal survival and axonal re-
generation, and have been widely investigated in animal
models of acute CNS injury or ischemia [16,21-24].
The immunosuppressant mycophenolate mofetil
(MMF) is clinically established for prevention of allograft
rejection after solid-organ transplantation [25]. After ad-
ministration, the morpholino-ester pro-drug is immedi-
ately hydrolyzed to the active compound mycophenolic
acid, which in turn is a selective and reversible inhibitor
of inosine 5-monophosphate dehydrogenase (IMPDH),
the rate-limiting enzyme of the de novo purine-synthesis
pathway [26-28]. The non-competitive inhibition is five-
fold more potent with the type II isoform of IMPDH
(IMPDH2), which is preferentially upregulated in acti-
vated leucocytes, whereas isoform I is constitutively
expressed in most cell types, resulting in an almost
specific inhibition of proliferation in activated leucocytes
[29].
We have previously shown that MMF exerts a potent
neuroprotective activity on excitotoxically lesioned orga-
notypic hippocampal slice cultures (OHSCs) and inhibits
microglial and astrocytic proliferation when administered
concomitantly with lesion induction [30]. In addition,
MMF effectively suppresses lipopolysaccharide (LPS)-sti-
mulated microglial and astrocytic activation and consecu-
tive secretion of pro-inflammatory mediators [31] by
inhibition of enzymatic activity of inducible nitric oxide
synthase, among other effects [32]. Furthermore, treat-
ment with mycophenolate mofetil strongly improves the
preservation of myelinated long-range projections in vitro
[33] and axonal regeneration in vivo [34].
These promising studies raise the possibility that im-
mediate MMF administration might be useful for the
treatment of acute CNS lesions. However, little is known
about the effective time-frame in which MMF treatment
can still be applied without inducing widespread
immunosuppression.
Thus, we assessed the effects of MMF on the temporal
dynamics of microglial and astrocytic proliferation and
apoptosis after acute excitotoxicity in OHSCs, and ana-
lyzed MMF-mediated effects on scar formation in the
scratch-wound model.
Methods
All animal experiments were performed in accordance
with the Policy on Ethics and the Policy on the Use of
Animals in Neuroscience Research as approved by the
directive 2010/63/EU of the European Parliament and of
the Council of the European Union on the protection of
animals used for scientific purposes.
Preparation and maintenance of organotypic
hippocampal slice cultures
For the preparation of OHSCs, 8-day-old Sprague–Dawley
rats were decapitated, and the brains were dissected under
sterile conditions according to standard protocols [35].
After removal of the frontal pole and the cerebellum, the
brains were placed in preparation medium at 4°C; this
preparation medium consisted of minimal essential
medium (MEM; Gibco BRL Life Technologies, Eggenstein,
Germany) pH 7.35 including 1%v/v glutamine (Gibco).
Subsequently, these preparations were sliced into sections
350 μm thick on a vibratome (Vibratom VT 1200 S; Leica
Microsystems AG, Wetzlar, Germany). Approximately six
to eight OHSCs were obtained from each brain, and were
immediately transferred into cell- culture inserts with a
pore size of 0.4 μm (Falcon, BD Bioscience Discovery Lab-
ware, Bedford, MA, USA), which were placed in six-well
culture dishes (Falcon) and fed with 1 ml culture medium
per well. The culture medium consisted of 50%v/v MEM,
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25%v/v Hanks’ balanced salt solution supplemented with
185 mg/L CaCl2 and 100 mg/L MgCl2, 25%v/v normal
horse serum (all Gibco), 2%v/v glutamine, 1 μg/ml insulin
(Boehringer, Mannheim, Germany), 1.2 mg/ml glucose
(Braun, Melsungen, Germany), 0.1 mg/ml streptomycin,
100 U/ml penicillin and 0.8 μg/ml vitamin C (Sigma-
Aldrich Chemicals, Deisenhofen, Germany) at pH 7.4. The
culture dishes were incubated for 6 days at 35°C in a fully
humidified atmosphere with 5% CO2 and the culture
medium was changed on alternate days. Mycophenolate
mofetil (CellCept; Roche, Grenzach-Wyhlen, Germany)
was diluted in cell-culture medium for application to
OHSCs at a previously determined effective concentration
of 100 μg/ml [30]. The nucleoside guanosine (Sigma-
Aldrich Chemicals) was applied at a concentration of
100 μmol/l at 6 days in vitro before MMF treatment to
counteract MMF-induced purine depletion.
Treatment protocols of organotypic hippocampal slice
cultures
The preparations were randomly divided into different
experimental groups and treated according to the fol-
lowing protocols:
Control
Unlesioned OHSCs (n = 57) served as control slices, and
were kept in culture medium for 9 days in vitro without
any treatment.
NMDA
At 6 days in vitro, OHSCs (n = 43) were lesioned with
NMDA (50 μmol/l; Sigma-Aldrich Chemicals) for 4
hours, and thereafter kept in culture medium for an-
other 3 days in vitro.
NMDA time series
At 6 days in vitro, OHSCs were lesioned with NMDA
for 4 hours, and subsequently fixed at 12, 24, 36, 48 or
72 hours after lesion induction (Figure 1 A).
Continuous MMF treatment after injury
OHSCs were kept in culture medium for 6 days in vitro,
lesioned with NMDA (50 μmol/l) for 4 hours, and trea-
ted with MMF 100 μg/ml at different starting time
points after injury (4 hours, n = 17; 8 hours, n = 20; 12
hours, n = 24; 16 hours, n = 15; 24 hours, n = 18; 36
hours, n = 16; 48 hours, n = 17) for another 3 days
in vitro, (Figure 2A).
Time frame of MMF treatment after injury
OHSCs were kept in culture medium for 6 days in vitro,
lesioned with NMDA (50 μmol/l) for 4 hours and there-
after treated with MMF (100 μg/ml) within a certain
time window (i) 4 to 8 hours after injury (n = 21), (ii) 4
to 24 hours after injury (n = 26), (iii) 4 to 48 hours after
injury (n = 15), (iv) 12–36 hours after injury (n = 23) and
(v) 24 to 48 hours after injury (n = 15), (Figure 3A).
Determination of neuronal cell death and confocal laser
scanning microscopy
To visualize the pyknotic nuclei of degenerating neurons,
OHSCs at 9 days in vitro were incubated with PI 5 μg/ml
(Chemicon, Nuernberg, Germany) for 2 hours before fix-
ation. The use of PI as an indicator for cell viability and for
identification of degenerating neurons in OHSCs has been
established previously [36,37]. After rinsing with 0.1 mol/l
phosphate buffer, slices were fixed with a 4%w/v solution
of paraformaldehyde in 0.2 mol/l phosphate buffer
overnight.
The pre-fixed OHSCs were then removed from the cell
culture inserts, placed into 24-well plates (Falcon), and
washed for 10 minutes with PBS containing 0.03% v/v Tri-
ton X-100 (PBS/Triton X-100) for 10 minute. The slices
were then incubated with normal goat serum (diluted 1:20
in PBS/Triton X-100) for 1 hours, and stained with fluor-
escein isothiocyanate (FITC)-conjugated Griffonia simpli-
cifolia IB4 (Vector laboratories, Burlingame, CA, USA)
diluted 1:50 in PBS/Triton X-100 containing 0.25% (w/v)
bovine serum albumin for 3 hours. The slices were washed
with PBS/Triton X-100 for 10 minute and finally mounted
under coverslips using fluorescent mounting medium
(Dako Diagnostika GmbH, Hamburg, Germany).
OHSCs were analyzed and imaged with a confocal laser
scanning microscope (LSM 510 Meta, Zeiss, Goettingen,
Germany). For detection of PI+ nuclei of degenerating neu-
rons, monochromatic light at 543 nm and an emission
bandpass filter of 585 to 615 nm were used. For
visualization of IB4
+ microglial cells, monochromatic light at
488 nm with a dichroic beam splitter (FT 488/543) and an
emission band-pass filter of 505 to 530 nm were used.
Confocal images were obtained at 160-fold magnification
at a resolution of 1024 × 1024 pixels. Using the mid-stag
mode and the Z-mode of the confocal microscope, the op-
tical mid-stag and the two adjacent optical sections (2 μm
thick) of the granule cell layer (GCL) in the dentate gyrus
(DG) were obtained and converted into a binary image.
Subsequently, numbers of IB4
+ microglial cells and PI+ de-
generating neurons were counted in the GCL of the DG
(cells/GCL) as previously described [14,37,38]. Lesioned
OHSCs treated with MMF at different time points or
within specific time frames after injury were compared with
OHSCs treated with NMDA alone.
Analyses of microglial and astrocytic proliferation and
apoptosis
For analyses of proliferation and apoptosis indices of
microglial cells and astrocytes, NMDA-lesioned OHSCs
were fixed at 12, 24, 36, 48 and 72 hours after injury.
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Figure 1 Temporal dynamics of cellular responses after excitotoxic lesion. (A) Treatment protocols. (B) (Upper panel) Immunoblot analyses
of inosine 5-monophosphate dehydrogenase (IMPDH)2 and β-actin at different time points post-lesion. N-methyl-D-aspartate (NMDA) lesion
affected IMPDH2 immunoreactivity over time. (Lower panel) Semiquantitative analyses of immunoblot data (n = 4) showed a significant reduction
in the amount of IMPDH2 at 36 and 48 hours after injury compared with the values at 12 hours (*P< 0.05). (C) Confocal laser scanning
microscopy images, double-labeled with isolectin (I)B4 (microglial cells, green) or glial fibrillary acidic protein (GFAP) (astrocytes, green) each in
combination with Ki-67 (proliferating cells, red). Temporal patterns of (D) microglial and (E) astroglial proliferation indices after NMDA-mediated
excitotoxic lesion as shown by quantitative morphometry of Ki-67+ glial cell ratios (*P< 0.05 vs. control (CTL)). Microglial proliferation indices were
significantly increased from 12 hours to 48 hours, with maximum values at 24 hours post-lesion. Astrocytic proliferation indices were significantly
increased from 12 hours to 36 hours after injury. (F–G) Microglial and astroglial apoptosis indices after NMDA-mediated excitotoxic lesion as
measured by assessment of ratios of cleaved caspase-3-immunoreactive glial cells (*P< 0.05 vs. control (CTL)). The apoptosis indices of both
microglial cells and astrocytes were significantly increased between 24 and 72 hours, with a decline at 36 hours post-lesion. Scale bar = 50 μm.
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Figure 2 Effects of continuous mycophenolate mofetil (MMF) treatment from different time points after injury on neuronal survival
and microglial activation in organotypic hippocampal slice cultures (OHSCs). (A) Treatment protocols. (B) Confocal laser scanning
microscopy images in overview and higher magnification, double-labeled with propidium iodide (PI) (degenerating neurons, red) and IB4
(microglial cells, green). Untreated control (CTL) OHSCs had very good preservation of the hippocampal formation with almost no PI+ pyknotic
nuclei and only a few ramified IB4
+ microglial cells. Slices treated with NMDA 50 μmol/l for 4 hours had massive accumulation of amoeboid IB4+
microglial cells and a dramatic increase in PI+ neuronal nuclei. Delayed treatment (until 12 hours after injury) with MMF resulted in a significant
reduction of PI+ degenerating neurons. Numbers of microglial cells were reduced even with late administration of MMF (after 48 hours
post-injury). (C-D) Quantitative analyses of the effects of MMF on NMDA-lesioned OHSCs. The mean numbers of (C) PI+ degenerating neurons
and (D) IB4
+ microglial cells were calculated for each experimental group and compared with OHSCs treated with NMDA alone (*P< 0.05 vs.
NMDA). DG, dentate gyrus; Hi, hilus. Scale bars = 50 μm in overviews; 20 μm in insets.
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Figure 3 Mycophenolate mofetil (MMF) treatment in specific time frames after injury and effects of guanosine on neuroprotective and
antiproliferative properties of MMF. (A) Treatment protocols. (B,C) Quantitative analyses of the effects of short-term MMF treatment (100 μg/
ml) on neuronal survival and microglial activation in organotypic hippocampal slice cultures (OHSCs) when MMF was administered in different
time windows after injury. Mean numbers of (B) propidium iodide (PI)+ degenerating neurons and (C) IB4
+ microglial cells were calculated for
each experimental group, and compared with OHSCs treated with N-methyl-D-aspartate (NMDA) alone (*P< 0.05 vs. NMDA). MMF elicits strong
neuroprotective effects when administered within the time frame of 4 to 48 hours or even 12 to 36 hours after injury. However, treatment within
4 to 24 hours or 24 to 48 hours after injury likewise reduced numbers of IB4
+ microglial cells. (D,E) Quantitative analyses of guanosine effects.
Mean numbers of (D) PI+ degenerating neurons and (E) IB4
+ microglial cells were calculated for each experimental group and compared with
matched OHSCs that did not receive guanosine (*P< 0.05). Guanosine did not affect either neuronal viability or microglial activation when
applied to unlesioned control (CTL) OHSCs. In NMDA-lesioned OHSCs subjected to guanosine treatment, there was a significant reduction in the
numbers of PI+ degenerating neurons, whereas the numbers of IB4
+ microglial cells were unaffected. However, application of guanosine to OHSCs
that received MMF treatment within the 12 to 36 hour time window significantly reversed the antiproliferative reduction in IB4
+ microglial cells
without affecting MMF-dependent neuroprotection.
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Quadruple staining was performed using GFAP, IB4,
4’-6-diamidino-2-phenlyindole (DAPI) and Ki-67 or
cleaved caspase-3, respectively. OHSCs were removed
from the cell-culture insert membranes, washed with
PBS, and cryoprotected with ascending solutions of 10%,
20% and 30%w/v sucrose before being sectioned hori-
zontally at 12 μm thickness on a cryostat (CM3050 S;
Leica) at −23°C. Obtained sections were subsequently
mounted on microscope slides (Superfrost Plus; Gerhard
Menzel GmbH, Braunschweig, Germany) and air-dried.
Cryostat sections were washed with PBS/Triton X-100
for 10 minutes, pre-incubated with normal goat serum
(diluted 1:20 in PBS/Triton) for 30 minutes and incu-
bated with the primary antibody (rabbit anti- Ki-67,
diluted 1:200; DCS Innovative Diagnostik Systeme,
Hamburg, Germany) or (rabbit anti-cleaved caspase-3,
diluted 1:200; Cell Signalling Technology, Danvers, MA,
USA) for 12 hours. After washing with PBS-Triton X-
100, the slices were simultaneously incubated with the
secondary antibody (1:200, Alexa 568-conjugated goat
anti-rabbit IgG; Invitrogen) for 1 hour. Sections were
then incubated with a monoclonal rat anti-GFAP anti-
body (1:200, Dako) for 12 hours, washed, and incubated
with the secondary goat anti-rat Alexa 633-conjugated
antibody (1:200, Invitrogen) for 1 hour. Microglial cells
were stained with FITC-IB4 for 1 hour as described
above. Finally, nuclear staining was performed by appli-
cation of DAPI 100 ng/mL (Molecular Probes, Mobitec,
Goettingen, Germany) for 15 minutes.
Sections were then washed with PBS-Triton and dis-
tilled water for 10 minutes each, coverslipped with fluor-
escent mounting medium (Dako) and analyzed by
confocal laser scanning microscopy in multi-tracking
mode. Monochromatic light at 488, 543, and 633 nm
with a dichroic beam splitter (FT UV/488/543/633) was
used to visualize cellular nuclei (DAPI; excitation
405 nm, emission band-pass filter 420 to 480 nm),
microglial cells (FITC-IB4; excitation 488 nm, emission
band-pass filter 505 to 530 nm), astrocytes (GFAP; exci-
tation 633 nm, emission long pass 650 nm), proliferating
cells (Ki-67; excitation 543 nm, emission band-pass filter
585 to 615 nm) or cleaved caspase-3+ immunoreactive
cells (cleaved caspase-3; excitation 543 nm, emission
band-pass filter 585 to 615 nm).
Quantitative morphometry of organotypic hippocampal
slice cultures
Quantitative morphometry was used for determination
of the following parameters: 1) the number of PI+ degen-
erating neurons, 2) the number of IB4
+ microglial cells, 3)
the number of Ki-67+ proliferating cells and 4) the num-
bers of cleaved caspase-3+ immunopositive cells each
throughout the entire granule-cell layer of the DG using
ImageJ software (ImageJ 1.44p, National Institutes of
Health, USA). Proliferation indices were calculated as
the percentage of Ki-67+ proliferating microglial cells or
astrocytes related to the total number of respective glial
cells in DG. Correspondingly, apoptosis indices were
determined as the percentage of cleaved caspase-3+
immunopositive glial cells per total numbers of glial
cells.
Immunoblotting and semiquantitative analyses
For immunochemical analyses, hippocampal formations
of differentially treated OHSCs were used. Protein con-
centrations were determined by the dye-based method
of Bradford [39], and equivalent quantities were loaded
onto 12.5% SDS–PAGE gels. After gel electrophoresis,
the proteins were blotted onto nitrocellulose mem-
branes, which were then pre-incubated in blocking buf-
fer (5% milk, 25 mmol/l Tris–HCl, 150 mmol/l NaCl)
pH 7.5 to reduce non-specific binding of the antibody.
The nitrocellulose membranes were incubated overnight
with the aforementioned antibody against IMPDH2
(diluted 1:2000 in blocking buffer containing 0.2%
Tween 20). Binding of the primary antibody was visua-
lized using horseradish peroxidase-conjugated goat anti-
rabbit IgG and enhanced chemiluminescence (Thermo
Fisher Scientific, Barrington, IL, USA). For semiquantita-
tive analysis, the relative signal intensities of the immu-
noreactive bands were determined and standardized as
quotients of IMPDH2 intensity units per β-actin inten-
sity units.
Primary astrocyte cell cultures and scratch-wound model
analyses
Astrocyte cell cultures were prepared from p0-2 Spra-
gue–Dawley rat brains according to standard protocols
[40]. In brief, brains were treated with trypsin (4 mg/mL;
Boehringer) in Hank’s balanced salt solution without
Ca2+ or Mg2+ with DNAse (0.5 mg/mL; Worthington,
Bedford, MA, USA), and resuspended in 1 mL culture
medium, consisting of DMEM (Gibco), supplemented
with 10% FCS (Gibco), 1% glutamine (Boehringer), 100
U/mL penicillin and 0.1 mg/mL streptomycin (Sigma-
Aldrich Chemicals). The cell suspension was transferred
into tissue culture flasks (75 cm2; Falcon) and incubated
for 7 days in vitro. Astrocytic monolayers were subse-
quently treated with trypsin in PBS without Ca2+ or
Mg2+, and seeded onto poly-L-lysine coated coverslips in
24-well tissue culture plates (Falcon). Purity of astrocytic
cultures was verified by immunocytochemistry against
GFAP (GFAP+ astrocytes> 98%).
For in vitro scratch-wound model experiments, conflu-
ent astrocyte monolayers were wounded by scratching
with sterile plastic pipette tips. Scratched cultures
remained either untreated (control) or were treated with
MMF at a concentration of 1 μg/mL. At 0, 2, 6, 12, 24
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and 48 hours after scratching, astrocytes were fixed for
assays on cell proliferation, using anti-GFAP and anti-
Ki-67 immunofluorescence staining as described above.
Proliferation indices were calculated as the percentage of
Ki-67+ proliferating astrocytes related to the total num-
ber of astrocytes around the scratch-wound area. The
mean astrocytic gap widths were measured by image
analysis. The mean gap width of untreated (control) cul-
tures at baseline (immediately after scratching; 0 hours)
was defined as 100%. Data from other time points and
MMF treatment were presented as percentages of the
controls at baseline.
Statistical analysis
Data are presented as mean ± SEM. For statistical ana-
lysis the one-way ANOVA test was used followed by
Dunnett’s post hoc test or Bonferoni’s test for multiple
comparisons when the effect of MMF treatment on
numbers of PI+ degenerating neurons, IB4
+ microglial
cells, Ki-67+ proliferating cells, cleaved caspase-3-
positive cells, IMPDH signal intensities or gap widths,
respectively, was significant. P< 0.05 was considered
significant.
Results
Temporal dynamics of proliferation and apoptosis after
acute excitotoxic injury
To investigate temporal patterns of glial cell prolifera-
tion and apoptosis, indices of Ki-67 and cleaved caspase-
3 immunoreactive astrocytes and microglial cells were
assessed at different proximate time points after the
onset of acute excitotoxic lesion.
Unlesioned control OHSCs displayed low levels of Ki-
67+ proliferating microglial cells or astrocytes (8.1% and
7.3%, respectively) (Figure 1D,E). Correspondingly, apop-
tosis indices of control OHSCs were markedly low: only
2.2% microglial cells and 0.5% astrocytes were immunor-
eactive for cleaved caspase-3 (Figure 1F,G). After
NMDA-mediated excitotoxic lesion induction of OHSCs,
the fraction of proliferating microglial cells rapidly
increased within the first 12 hours post-lesion, and the
proliferation index reached its maximum at 24 hours
after injury (12 hours: 21.5%, P< 0.01; 24 hours: 43.2%,
P< 0.0001) (Figure 1 D). Thereafter the fraction of prolif-
erating microglial cells decreased from 31.7% at 36 hours
to 28.1% at 48 hours after injury (P< 0.001) and reached
almost control levels at 72 hours after injury (11.2% Ki-
67+ microglial cells, P> 0.05) (Figure 1D). Similarly,
astroglial proliferation indices increased most rapidly
within the first 12 hours post-lesion and reached a plat-
eau up to 36 hours (12 hours: 22.8%; 24 hours: 22.7%; 36
hours: 23.3%, P< 0.001), and thereafter fractions of pro-
liferating astrocytes steadily declined (48 hours: 13.3%; 72
hours: 2.8%, P >0.05) (Figure 1E).
In the aftermath of NMDA-induced excitotoxic injury,
the ratios of glial cells undergoing apoptotic conditions
increased steadily over time. At 12 hours post-lesion, the
microglial apoptosis indices remained unaltered com-
pared with unlesioned control OHSCs, but the ratio sig-
nificantly increased within 24 hours and continued to
increase until 72 hours after the initial lesion (12 hours:
4.8%, P> 0.05; 24 hours: 11.2%, P< 0.0001; 36 hours:
8.6%, P< 0.01; 48 hours: 11.3%, P< 0.0001; 72 hours:
9.1%, P< 0.001) (Figure 1F). The apoptosis indices of
astrocytes were similar to those seen with microglial
cells, but with significantly diminished apoptosis ratio at
36 hours post-lesion (12 hours: 4.0%, P> 0.05; 24 hours:
9.6%, P< 0.0001; 36 hours: 3.8%, P> 0.05; 48 hours:
6.2%, P< 0.001; 72 hours: 5.1%, P< 0.01) (Figure 1G).
Inosine 5-monophosphate dehydrogenase 2
immunoreactivity after N-methyl-D-aspartate-induced
lesion and mycophenolate mofetil treatment
IMPDH2 immunoreactivity was assessed in immuno-
blots at different time points after NMDA-mediated le-
sion induction of OHSCs at 6 days in vitro. The
antibody against IMPDH2 labeled a single band of
56 kDa, corresponding to the known molecular weight
of the enzyme. This band was found in unlesioned con-
trol OHSCs and its intensity gradually changed after
NMDA application when assessed at 12, 24, 36 and 48
hours post-lesion. IMPDH2 signal intensity standardized
to β-actin was significantly increased at 12 hours post-
lesion compared with intensities at 36 and 48 hours after
injury (P< 0.05) (Figure 1B).
Continuous mycophenolate mofetil treatment of N-
methyl-D-aspartate-lesioned organotypic hippocampal
slice cultures from different time points
In control OHSCs, the typical hippocampal cytoarchitec-
ture was well preserved (Figure 2B). Throughout all op-
tical sections almost no pyknotic PI+-nuclei and only a
few IB4
+ microglial cells were found (control: 1.5 PI+ and
10.8 IB4
+ cells/GCL) (Figure 2C,D) confirming excellent
preservation after 9 days in vitro under standard incuba-
tion conditions. Microglial cells, which were primarily
found in the molecular and plexiform layers of the DG
and hippocampus, exhibited a ramified phenotype with
highly branched processes.
OHSCs treated after 6 days in vitro for 4 hours with
50 μmol/l NMDA and analyzed after 9 days in vitro showed
massive neuronal damage, reflected by greatly increased
numbers of PI+ degenerating neurons exhibiting lumi-
nously stained condensed nuclei with occasional signs of
karyorrhexis in the GCL of the DG (Figure 2B). Quantita-
tive analysis of IB4
+ microglial cells confirmed that the num-
ber of microglial cells was likewise significantly increased
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compared with controls (NMDA: 138.9 PI+ and 55.1 IB4
+
cells/GCL, P< 0.001) (Figure 2C,D).
Continuous treatment of lesioned OHSCs with MMF
100 μg/ml significantly reduced the numbers of both PI+
degenerating neurons and of IB4
+ microglial cells in a
time-dependent manner (Figure 2C,D). When MMF
treatment was started at 4 hours after injury, the number
of PI+ pyknotic nuclei of degenerating neurons was sig-
nificantly decreased (4 hours: 82.1/GCL, P< 0.001)
(Figure 2B,C) compared with NMDA-lesioned cultures
only (NMDA: 138.9/GCL). The mean number of IB4
+
microglial cells correspondingly decreased significantly,
dropping from 55.1 cells/GCL to 16.1 cells/GCL
(P< 0.001) (Figure 2D). Similar neuroprotective effects
of MMF were seen when treatment was implemented at
8 hours after injury, which were paralleled by a signifi-
cant reduction in the number of microglial cells (8
hours: 83.2 PI+ cells/GCL, 24.1 IB4
+ cells/GCL, P< 0.001)
(Figure 2C,D). MMF administration from 12 hours post-
lesion still resulted in significant neuroprotection (12
hours: 106.5 PI+ cells/GCL, P< 0.01) (Figure 2C), but
the reduction in the mean number of PI+ cells was less
pronounced compared with the experimental groups
that received MMF earlier. Application of MMF at 12
hours after injury caused a similar reduction in numbers
of microglial cells compared with an application after 4
or 8 hours (12 hours: 27.1 IB4
+ cells/GCL, P< 0.001)
(Figure 2D). However, when MMF treatment was
delayed until 16 hours after excitotoxic injury, the neu-
roprotective effects were no longer visible, and teh num-
bers of PI+ degenerating neurons in the GCL of DG (16
hours: 125.6 PI+ cells/GCL, P> 0.05) (Figure 2C) were
now equivalent to those in OHSCs treated with NMDA
alone, whereas the number of microglial cells was still
considerably decreased (16 hours: 25.3 IB4
+ cells/GCL,
P< 0.001). Although no neuroprotective efficacy was
detected in excitotoxically lesioned OHSCs given MMF
at 24 (128.0 PI+ cells/GCL), 36 (138.8 PI+ cells/GCL) or
48 hours (153.6 PI+ cells/GCL, P> 0.05) (Figure 2C)
after injury, statistical analysis showed that the numbers
of IB4
+ microglial cells were consistently reduced (24
hours: 27.4 IB4
+ cells/GCL; 36 hours: 27.7 IB4
+ cells/GCL;
48 hours: 40.2 IB4
+ cells/GCL, P< 0.001) (Figure 2D)
even after late initiation of MMF administration.
Mycophenolate mofetil treatment in definite time
windows after injury
Treatment of OHSCs with MMF 100 μg/ml was per-
formed in specific time-frames to determine the window
of opportunity to achieve highest neuroprotective effi-
cacy. When MMF treatment was scheduled in an early
and short time window (4 to 8 hours after injury), there
was no effect on either the number of PI+ degenerating
neurons or the number of IB4
+ microglial cells in the DG
compared with NMDA-lesioned OHSCs (4 to 8 hours:
143.8 PI+ and 46.5 IB4
+ cells/GCL, P> 0.05) (Figure 3B,
C). Administration of MMF during the window of 4 to
24 hours after injury also did not elicit neuroprotective
effects on OHSCs (136.2 PI+ cells/GCL, P> 0.05)
(Figure 3B), but significantly decreased the numbers of
IB4
+ microglial cells (31.6 IB4
+ cells/GCL, P< 0.001)
(Figure 3C).
However, application of MMF within a broader time
window (4 to 48 hours after injury) significantly reduced
the numbers of PI+ neurons and IB4
+ microglial cells (4
to 48 hours: 99.3 PI+ and 31.5 IB4
+ cells/GCL, P< 0.001)
(Figure 3B,C). Correspondingly, a delayed and shortened
MMF treatment (12 to 36 hours after NMDA lesion)
significantly reduced the numbers of PI+ degenerating
neurons and IB4
+ microglial cells (12–36 hours: 105.8 PI+
and 23.2 IB4
+ cells/GCL, P< 0.01) (Figure 3B,C). In sub-
sequent experiments, this 12 to 36-hour time frame
served as a positive control for highest MMF efficacy.
When MMF application was delayed to 24 hours after
injury and lasted until 48 hours, the neuroprotective
effects were lost, although administration within this late
time window evenly reduced the mean numbers of
microglial cells counted 72 hours after injury (137.8 PI+
and 30.7 IB4
+ cells/GCL, P< 0.001) (Figure 3B,C).
Antagonization of mycophenolate mofetil-induced purine
depletion by pre-treatment with the nucleoside
guanosine
Application of guanosine 100 μmol/l on excitotoxically
lesioned OHSCs that were subjected to MMF treatment
was performed to investigate a possible antagonization
of the MMF-induced neuroprotective and antiprolifera-
tive effects by refilling the previously depleted purine
pools in glial cells.
Guanosine treatment on unlesioned control OHSCs
did not affect neuronal survival or microglial cell num-
bers (control + guanosine: 0.4 PI+ cells/GCL, 6.4 IB4
+
cells/GCL, P> 0.05) (Figure 3D,E), but it significantly
reduced the degree of neuronal cell death when applied
to NMDA-lesioned OHSCs (NMDA+guanosine: 97.4
PI+ cells/GCL, P< 0.001) (Figure 3D) without affecting
the number of IB4
+ microglial cells (57.2 IB4
+ cells/GCL,
P> 0.05) (Figure 3E). When OHSCs subjected to MMF
administration within the crucial neuroprotective 12 to
36-hour time window received guanosine pre-treatment,
no changes in the neuroprotective efficacy of MMF were
seen (MMF 12 to 36 hours + guanosine: 92.6 PI+ cells/
GCL, P> 0.05) (Figure 3D). Similarly, there was no sig-
nificant difference in the number of PI+ degenerating
neurons compared with lesioned OHSCs treated with
guanosine alone (P> 0.05) (Figure 3D). However, pre-
treatment with guanosine potently counteracted MMF-
mediated reductions in the number of microglial cells,
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as shown by significant increases in the number of IB4
+
microglial cells in GCL of DG (MMF 12 to 36 hours +
guanosine: 43.1 IB4
+ cells/GCL, P< 0.001) (Figure 3E).
Effects of mycophenolate mofetil on glial proliferation
and apoptosis
MMF treatment on NMDA-lesioned OHSCs within the
crucial neuroprotective 12 to 36-hour time window sig-
nificantly reduced both microglial and astroglial prolif-
eration indices assessed at 36 hours post-lesion (MMF
12 to 36 hours: 7.9% Ki-67+ microglial cells and 4.4%
astrocytes, P< 0.001) (Figure 4B,C). However, although
MMF administration during the later time window of 24
to 48 hours after injury also significantly reduced the
fraction of Ki-67+ proliferating microglial cells, it did not
alter the indices of astroglial proliferation assessed at 48
hours post-lesion (MMF 24 to 48 hours: 16.1% Ki-67+
microglial cells, P< 0.01; 9.3% astrocytes, P> 0.05)
(Figure 4B,C).
Notably, treatment with MMF did not affect indices of
either microglial or astroglial apoptosis when applied
within the 12 to 36-hours or 24 to 48-hour time frames
(MMF 12 to 36 hours: 5.7% caspase-3+ microglial cells
and 2.3% astrocytes; MMF 24 to 48 hours: 10.5%
caspase-3+ microglial cells and 5.3% astrocytes, P> 0.05)
(Figure 4E,F).
Scratch-wound model: Effects of mycophenolate mofetil
on astrocyte migration and proliferation
To address the question of whether MMF can directly
modulate astrogliosis, the in vitro scratch-wound model
was used to determine the effects of MMF on mechan-
ical injury-induced astrocyte proliferation. Ratios of Ki-
67+ reactive astrocytes around the wounded area were
evaluated to determine scratch injury-induced astrocyte
proliferation.
At 12 hours after scratching, the numbers of astrocytes
within and next to the wound site had increased and the
respective cytoplasmic processes extended to the
denuded area. Cell proliferation adjacent to the wound
site was significantly enhanced from 12 hours after the
scratch procedure (12 hours: 41.3%, 24 hours: 64.1%,
and 48 hours: 76.9% Ki-67+ proliferating astrocytes,
P< 0.01) (Figure 5A). Accordingly, high rates of prolif-
eration led to a steady closing of the gap until cell dens-
ity approached confluence at 48 hours post- scratching
compared with control cultures at 0 hours (P< 0.001)
(Figure 5B). Pre-treatment of astrocytes with MMF 1 μg/
ml significantly decreased the scratch injury-induced
fraction of Ki-67+ astrocytes at 24 and 48 hours com-
pared with controls at the same time points (24 hours:
23.6% and 48 hours: 17.8%, respectively, P< 0.001)
(Figure 5A). The reduced rates of proliferation after
MMF treatment diminished the capacity of cell
migration and glial scar formation as shown by the lack
of gap closure (P< 0.001) (Figure 5B).
Discussion
In the aftermath of acute brain and spinal cord injuries,
neuroinflammatory processes induce various cellular and
molecular reactions, accompanied by rapid activation of
both microglial cells and astrocytes. However, the mode
and dimension of glial activation can even exacerbate
the original extent of neuronal damage, with potentially
harmful effects on neuronal survival, axonal regrowth,
or restitution of complex network functions [41-43].
Based on this hypothesis, effective suppression of glial
activation in a crucial time frame during the acute phase
of pathophysiological responses would promote neur-
onal integrity. Several immunosuppressive substances
possess the capacity to inhibit either microglial or astro-
cytic activation, resulting in significant neuroprotection
in models of acute CNS lesion, as reviewed previously
[44].
In previous studies, we have shown that treatment
with the immunosuppressant MMF significantly reduces
the extent of neuronal damage [30] and strongly pro-
motes integrity of myelinated long-range projections
when applied simultaneously with acute excitotoxic le-
sion induction [33]. The neuroprotective effects of MMF
seemed to be indirectly mediated by counteraction of ex-
cessive cytokine secretion and proliferation of glial cells,
which are hallmarks of secondary injury cascades [31].
Because clinically suitable drugs need to provide pro-
tection even if delivered hours after an incident (when
patients can eventually be treated under clinical condi-
tions), we analyzed in the present study the effects of
MMF on NMDA-induced temporal patterns of glial pro-
liferation and apoptosis, determined the time frame dur-
ing which MMF elicits optimum neuroprotection, and
investigated the role of MMF on glial scar formation.
The well-established experimental model of OHSC was
used, which enables analysis of neuron–glia interactions
and temporal patterns of excitotoxic neuronal demise
without the presence of confounding factors such as in-
flammatory cells infiltrating from the blood [45-47].
Microglial cells seem to be the only immunocompetent
cell type in this model, as blood-borne monocytes and T
lymphocytes are apparently absent [48]. Thus, OHSCs
are suitable to analyze the effects of MMF on glial cells
specifically in the context of neuroprotection.
Knowledge about the temporal patterns of glial prolif-
eration and apoptosis after NMDA lesion is of crucial
significance, as the excitotoxicity-mediated neuronal cell
decline is generally accompanied by reactive glial cell re-
cruitment and proliferation, and by activation of various
apoptosis-related signal transduction pathways that in
turn have the potential to exacerbate neuronal injury.
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Exposure of OHSCs to NMDA after 6 days in vitro
induced defined, quantifiable, and reproducible damage
to granule cells of the DG, resulting in a pronounced in-
crease in the number of proliferating astrocytes and
microglial cells in the early phase after the induction of
excitotoxic damage. The proliferation rates of microglial
cells were increased to their highest level at 24 hours
post-lesion but declined to control levels at 72 hours
after injury. Comparably lower proliferation rates were
found in astrocytes, although the ratios also increased
Figure 4 Effects of mycophenolate mofetil (MMF) treatment on glial apoptosis and proliferation. (A) High-magnification confocal laser
scanning microscopy images, double-labeled with Ki-67 (proliferating cells, red) in combination with either isolectin (I)B4 (microglial cells, green)
or glial fibrillary acidic protein (astrocytes, green). Effects of MMF on (B) microglial and (C) astroglial proliferation indices at 36 hours or 48 hours
post-lesion compared with lesioned organotypic hippocampal slice cultures (OHSCs) that received additional MMF treatment within 12 to 36
hours or 24 to 48 hours, respectively (*P< 0.05). (D) Confocal laser scanning microscopy images at high magnification, double-labeled with
cleaved caspase-3 (apoptotic cells, red) with either IB4 (microglial cells, green) or GFAP (astrocytes, green). (E,F) Effects of MMF on microglial and
astroglial apoptosis indices at 36 or 48 hours post-lesion compared with lesioned OHSCs that received additional MMF treatment within 12–36
hours or 24 to 48 hours, respectively (*P< 0.05). MMF treatment within the crucial neuroprotective 12–36-hour time window potently attenuated
microglial and astrocytic proliferation, but did not affect rates of glial apoptosis. Application of MMF within 24 to 48 hours post-lesion significantly
reduced microglial proliferation but did not affect either astrocytic proliferation or glial apoptosis. Scale bars = 25 μm.
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significantly from 12 to 36 hours post-lesion. These find-
ings indicate that MMF treatment should be started
within the first 12 hours after injury at the latest, and
should be maintained until 36 hours after injury.
Although excitotoxin-induced neurodegeneration can-
not be categorized as one singular mechanism of cell
death, but rather involves a combination of necrotic,
apoptotic, and autophagic processes [49], key features of
apoptosis such as internucleosomal degradation, chromo-
some fragmentation, and activation of caspases are hall-
marks of excitotoxic neuronal death [50,51]. In this
regard, we found that in both microglial cells and astro-
cytes, apoptotic conditions were significantly augmented
24 hours post-lesion and remained increased until 72
hours post-lesion. Notably, quantities of the rate-limiting
enzyme IMPDH2 were significantly diminished at 36 and
48 hours after NMDA application, which may be a
counter-regulation to exorbitantly increased proliferation
rates and might also account for the increased apoptosis
indices. These findings emphasize the importance of
schedule of administration in the neuroprotective efficacy
of MMF.
In fact, delayed but continuous application of MMF
on NMDA-lesioned OHSCs resulted in significant neu-
roprotection only when treatment was implemented at
the latest at 12 hours post-lesion. The neuroprotective
effects were most pronounced when MMF was applied
earlier after the lesion at 4 hours or 8 hours after injury.
Neuroprotective effects were paralleled by significant
reductions in numbers of IB4
+ microglial cells, thus sug-
gesting that a main source of neuroprotection is a conse-
quence of a potent inhibition of activated, proliferating
and neurotoxic glial cells. Previous studies on the time
course of excitotoxic neuronal injury after NMDA appli-
cation showed that numbers of PI+ neurons increase
rapidly till 24 hours post-lesion and reach a plateau after
36 hours which persists until 72 hours post-lesion [52].
Therefore, late application of MMF will not significantly
change the extent of neuronal demise but still be able to
effectively suppress glial activation and proliferation.
To figure out the time of efficacy of MMF treatment,
we performed a series of experiments with applications
of MMF within defined time windows. The crucial time
frame in which MMF application displayed the most po-
tent inhibition of glial activation accompanied by signifi-
cant neuroprotection was in between 12 hours till 36
hours after injury, being in accordance to the above
described temporal patterns of neuronal demise. In fur-
ther investigations on the effects of mycophenolate
mofetil, this crucial time frame served as positive control
of highest MMF efficacy.
To verify the hypothesis that inhibition of the enzyme
IMPDH and subsequent depletion of the purine pool was
responsible for the observed effects of MMF, the nucleoside
guanosine was applied to refill the purine pools and conse-
quently reverse the MMF-mediated effects. In previous
studies, guanosine application was found to potently re-
verse the inhibitory effects of MMF on the proliferation of
LPS-stimulated primary astrocytes and microglial cells [31].
In the current study, guanosine application to unlesioned
control OHSCs after 6 days in vitro did not impair neur-
onal viability or numbers of microglial cells. However,
guanosine treatment of NMDA-lesioned OHSCs resulted
in significant neuroprotection without reductions in micro-
glial cells, indicating direct neuroprotective effects on neu-
rons. In fact, guanosine and guanine nucleotides have
emerged as strongly neuroprotective agents that act by
Figure 5 Effects of mycophenolate mofetil (MMF) on astroglial
proliferation and scar formation in in vitro scratch-wound
model. (A) Astroglial proliferation indices in astrocyte cell cultures
after mechanical scratch injury as shown by quantitative
morphometry of Ki-67+ astroglial cell ratios at different time points
post-lesion. Untreated control cultures had significantly increased
rates of proliferating astrocytes from 12 hours post-lesion compared
with baseline (0 hours). Continuous treatment with MMF 1 μg/ml
potently attenuated astrocytic proliferation at 24 and 48 hours
post- scratching compared with matched control cultures
(*P< 0.05). (B) Quantitative measurements of scratch-gap widths as
measured by image analysis, normalized on the mean gap width of
control cultures at 0 hours. Untreated control cultures had constant
migration of astrocytes towards the scratch-induced gap over time,
leading to gap closure at 48 hours post-lesion. MMF treatment
inhibited reactive astrogliosis. No significant changes were found in
gap widths compared with controls at 0 hours (*P< 0.05).
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directly counteracting glutamate excitotoxicity [53]. Guan-
ine nucleotides are thought to act as glutamate receptor
antagonists [54] without affecting the binding capabilities of
glutamate or its analogs to glutamate receptors [55,56].
Investigations into the molecular mechanisms underlying
the neuroprotective activity indicate that guanosine pro-
motes neuroprotection depending on Ca2+-activated K+
channels, G-protein-coupled receptors, and modulation of
protein kinase (PK)A, PKC, mitogen-activated protein kin-
ase, and phosphatidylinositol-3 kinase pathways in slices
subjected to oxygen and glucose deprivation [57-61]. Ac-
cordingly, strong innate neuroprotective activity and the
various pleiotropic effects of guanosine led to decreased
numbers of degenerating neurons that could not further be
reduced by MMF treatment. By contrast, application of
guanosine to lesioned OHSCs subjected to MMF treatment
potently antagonized the strong reductions in the numbers
of microglial cells. These findings imply that the MMF-
mediated antiproliferative effects depend on depletion of
purine metabolites as a consequence of IMPDH inhibition.
The apparent antagonization of MMF effects by sub-
stitution of purines should be distinguished from various
independent guanosine-induced trophic responses on
glial cells. Guanosine has been shown to stimulate prolif-
eration of astrocytes [62,63], and to induce the synthesis
and release of neurotrophic and pleiotrophic factors by
astrocytes and microglial cells [64,65]. Thus, the various
pleiotropic effects described above make guanosine a
very sophisticated candidate for the treatment of neur-
onal injury in vitro. However, the strongly hydrophilic
nature of this compound will reduce its capability to
enter the brain by passing the blood–brain-barrier
in vivo.
To further investigate the cellular effects of MMF on
astrocytes and microglial cells, proliferation and apop-
tosis assays and scratch-wound model experiments were
performed. Treatment of NMDA-lesioned OHSCs with
MMF significantly diminished the fraction of Ki-67+
proliferating glial cells when treatment was implemented
within the crucial 12 to 36-hour neuroprotective time
frame, confirming observations of previous studies on
LPS-stimulated primary microglial cells and astrocytes
[31]. Our present finding of reduced proliferation of
microglial cells and astrocytes under the influence of
MMF indicates that this substance exerts direct antipro-
liferative effects on both investigated glial cell types. In
addition, MMF has been reported to inhibit the prolif-
eration of various other cell types such as lymphocytes,
fibroblasts, mesangial cells, and smooth muscle cells
[66-69]. The antiproliferative effect of MMF seems to be
based on arrest of the cell cycle in S phase, as was
shown in human T cells and monocytes [70]. However,
MMF treatment of NMDA-lesioned OHSCs within the
crucial 12 to 36-hour time window did not promote or
inhibit the initiation of apoptosis.
Similar effects were seen in the in vitro scratch-wound
model of confluent astrocyte monolayers. The direct mech-
anical injury is generally accompanied by reactive astroglial
scar formation along the lesion site. In confluent mono-
layers of astrocytes, injuries such as the scratch-induced
mechanical break-up of cell–cell connections result in re-
active astrocytic activation both in directly wounded cells
and in larger cell populations in non-wounded areas
throughout the culture. Consecutive signals are thought to
spread through intercellular junctions [71] and by release of
soluble factors such as cytokines or growth factors [72-74].
Activated astrocytes exhibit characteristic morphological
signs of activation such as elongation of hypertrophic pro-
cesses by realignment and expansion of the GFAP-
intermediate filament network or hypertrophy, being both
essential for migratory and proliferative responses [75,76].
After the scratch procedure, significant increases were
seen in the rate of cell proliferation, predominantly within
and around the wound from 12 hours after the scratching
procedure until confluence was restored after 48 hours. Ex-
perimental groups treated with MMF had a significant de-
crease in the fraction of Ki-67+ cells at 24 and 48 hours
after scratching compared with control groups. Further-
more, the scratch-induced gap in these groups was not
closed even at 48 hours post- scratching. These findings
confirm the inhibitory effects of MMF on astrocyte prolif-
eration, migration, and scar formation.
The modulatory and antiproliferative effects of MMF on
microglial cells and astrocytes without direct effects on
neurons strengthen the view that this immunosuppressive
agent exerts its neuroprotective activity by inhibiting the
potentially neurotoxic pro-inflammatory responses that are
carried largely by microglia and astrocytes [31]. MMF has
not been clinically used in the treatment of acute brain or
spinal cord injury in humans to date, but there are reports
on neurological benefits of this therapy in various chronic
neurological disorders. MMF has been used in the treat-
ment of refractory multiple sclerosis [77,78], multifocal
motor neuropathy [79] and chronic inflammatory poly-
neuropathy [80]. Against the background of strongly bene-
ficial effects on neuronal survival and recovery in
numerous in vitro studies in combination with promising
clinical observations, MMF might be a future candidate for
the treatment of acute CNS injuries in humans.
However, despite its broad immunosuppressive abilities
making MMF an efficacious drug for transplant and auto-
immune diseases, the conceivable risk of infectious compli-
cations should be considered. Recipients of solid-organ
transplants who receive MMF as part of their post--
transplant immunosuppressive regimen seem to have
increased susceptibility to infections [81,82] especially cyto-
megalovirus [83]. However, infectious complications are
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seen predominantly more than 1 month after initiation of
MMF treatment, thus an association with post-transplant
renal insufficiency was assumed [84].
In contrast to the long-term applications of MMF, our
results indicate that use of MMF as a pharmacological
intervention after excitotoxic injury is required only
within the first days after injury, thus the risk of post-
lesion infections is likely to be low. Nevertheless, in vivo
experiments are needed to clarify the short-term risks of
MMF treatment.
Conclusions
Taken together, our findings emphasize the therapeutic
potential of MMF after acute excitotoxic brain injury.
Our results indicate that: 1) delayed administration of
MMF until 12 hours after injury potently reduces the ex-
tent of secondary neuronal damage; 2) MMF application
within the crucial 12 to 36-hour time frame most effect-
ively repealed neuroinflammatory responses and resulted
in significant neuroprotection; 3) the neuroprotective
agent guanosine antagonized the inhibitory effects of
MMF on glial cell activation; 4) MMF effectively sup-
pressed both microglial and astroglial proliferation; 5)
apoptosis of glial cells in the aftermath of excitotoxicity
was not affected by MMF, and 6) MMF potently coun-
teracted reactive astrogliosis in vitro.
These findings emphasize the potential of MMF as a
promising and valuable therapeutic candidate in condi-
tions such as cerebral ischemia, spinal cord injury, or
trauma.
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